Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $732,750.00 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00. Following the transaction, the chief executive officer now directly owns 1,309,487 shares of the company’s stock, valued at $63,968,439.95. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.58, for a total transaction of $698,700.00.
• On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.

Apogee Therapeutics Stock Down 16.6 %

Apogee Therapeutics stock traded down $8.16 during trading hours on Friday, hitting $41.05. The stock had a trading volume of 1,366,016 shares, compared to its average volume of 509,403. The stock has a market capitalization of $1.85 billion, a P/E ratio of -16.96 and a beta of 2.26. Apogee Therapeutics, Inc. has a 12-month low of $30.84 and a 12-month high of $72.29. The stock’s 50-day moving average price is $48.70 and its 200-day moving average price is $48.90.

Analyst Ratings Changes

Several analysts have issued reports on APGE shares. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Wedbush raised their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $89.71.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in Apogee Therapeutics by 35.7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after buying an additional 1,267,451 shares during the period. Driehaus Capital Management LLC lifted its position in Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after purchasing an additional 54,107 shares during the last quarter. Perceptive Advisors LLC lifted its position in Apogee Therapeutics by 2.2% during the second quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after purchasing an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in Apogee Therapeutics by 41.2% during the second quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock valued at $32,908,000 after purchasing an additional 244,190 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after acquiring an additional 82,978 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.